Search Results

Romeo, Juliet, and Statutory Rape.

• Authors : Bierie DM; 1 U.S. Department of Justice, Alexandria, VA, USA.; Budd KM

Subjects: Crime Victims/Crime Victims/Crime Victims/*statistics & numerical data ; Criminals/Criminals/Criminals/*statistics & numerical data ; Rape/Rape/Rape/*statistics & numerical data

• Source: Sexual abuse : a journal of research and treatment [Sex Abuse] 2018 Apr; Vol. 30 (3), pp. 296-321. Date of Electronic Publication: 2016 Jul 15.Publisher: Sage Publications Country of Publication: United States NLM ID: 9506704 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

6-Gingerdione Reduces Apoptotic Conditions in HepG2 Cells and Inhibits Inflammatory Cytokine Gene Expression in Alcoholic Liver Injured Zebrafish Larvae.

• Authors : Guru A; Department of Conservative Dentistry and Endodontics, Saveetha Dental College and Hospitals, SIMATS, Chennai 600 077, Tamil Nadu, India.; Manjunathan T

Subjects: Antioxidants*/Antioxidants*/Antioxidants*/pharmacology ; Antioxidants*/Antioxidants*/Antioxidants*/metabolism ; Zebrafish*/Zebrafish*/Zebrafish*/metabolism

• Source: Chemistry & biodiversity [Chem Biodivers] 2023 Jan; Vol. 20 (1), pp. e202200959. Date of Electronic Publication: 2022 Dec 27.Publisher: Verlag Helvetica Chimica Acta Country of Publication: Switzerland NLM ID: 101197449 Publication Model: Print-Electronic Cited Medium:

Record details

Gastrointestinal infections and gastrointestinal haemorrhage are underestimated but serious adverse events in chimeric antigen receptor T-cell recipients: A real-world study.

• Authors : Song Z; Department of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China.; Wang Y

• Source: Cancer gene therapy [Cancer Gene Ther] 2024 Mar 28. Date of Electronic Publication: 2024 Mar 28.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 9432230 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Green Synthesized Silver Nanoparticles Using Lactobacillus Acidophilus as an Antioxidant, Antimicrobial, and Antibiofilm Agent Against Multi-drug Resistant Enteroaggregative Escherichia Coli.

• Authors : Abishad P; Department of Veterinary Public Health, College of Veterinary and Animal Sciences, Pookode, Kerala Veterinary and Animal Sciences University, Lakkidi Post, Wayanad, 673 576, India.; Vergis J

Subjects: Anti-Infective Agents*/Anti-Infective Agents*/Anti-Infective Agents*/pharmacology ; Metal Nanoparticles* ; Probiotics*

• Source: Probiotics and antimicrobial proteins [Probiotics Antimicrob Proteins] 2022 Oct; Vol. 14 (5), pp. 904-914. Date of Electronic Publication: 2022 Jun 17.Publisher: Springer Country of Publication: United States NLM ID: 101484100 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.

• Authors : Westin JR; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Kersten MJ

Subjects: Antigens, CD19/Antigens, CD19/Antigens, CD19/*therapeutic use ; Lymphoma, Large B-Cell, Diffuse/Lymphoma, Large B-Cell, Diffuse/Lymphoma, Large B-Cell, Diffuse/*therapy ; Neoplasm Recurrence, Local/Neoplasm Recurrence, Local/Neoplasm Recurrence, Local/*therapy

• Source: American journal of hematology [Am J Hematol] 2021 Oct 01; Vol. 96 (10), pp. 1295-1312. Date of Electronic Publication: 2021 Aug 13.Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.

• Authors : Schuster SJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: .; Tam CS

Subjects: Immunotherapy, Adoptive*/Immunotherapy, Adoptive*/Immunotherapy, Adoptive*/adverse effects ; Immunotherapy, Adoptive*/Immunotherapy, Adoptive*/Immunotherapy, Adoptive*/mortality; Lymphoma, Large B-Cell, Diffuse/Lymphoma, Large B-Cell, Diffuse/Lymphoma, Large B-Cell, Diffuse/*therapy

• Source: The Lancet. Oncology [Lancet Oncol] 2021 Oct; Vol. 22 (10), pp. 1403-1415. Date of Electronic Publication: 2021 Sep 10.Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Pro-inflammatory cytokine molecules from Boswellia serrate suppresses lipopolysaccharides induced inflammation demonstrated in an in-vivo zebrafish larval model.

• Authors : Siddhu NSS; Department of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science and Technology, 603 203, Kattankulathur, Chennai, Tamil Nadu, India.; Guru A

Subjects: Boswellia*/Boswellia*/Boswellia*/chemistry ; Triterpenes*/Triterpenes*/Triterpenes*/chemistry; Animals

• Source: Molecular biology reports [Mol Biol Rep] 2022 Aug; Vol. 49 (8), pp. 7425-7435. Date of Electronic Publication: 2022 Jun 18.Publisher: Reidel Country of Publication: Netherlands NLM ID: 0403234 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-4978

Record details

In vitro activity of ceftazidime-avibactam against Gram-negative strains in Chile 2015-2021.

• Authors : Torres-Castillo LC; Medical Affairs, Pfizer Andean Cluster, Santiago, Chile.; Fandiño C

Subjects: Ceftazidime*/Ceftazidime*/Ceftazidime*/pharmacology ; Ceftazidime*/Ceftazidime*/Ceftazidime*/therapeutic use ; Amikacin*/Amikacin*/Amikacin*/pharmacology

• Source: Journal of global antimicrobial resistance [J Glob Antimicrob Resist] 2023 Dec; Vol. 35, pp. 143-148. Date of Electronic Publication: 2023 Sep 13.Publisher: Published by Elsevier Ltd. on behalf of International Society of Chemotherapy for Infection and Cancer Country of Publication: Netherlands NLM ID:

Record details

Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG).

• Authors : Rattanathammethee T; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. .; Norasetthada L

Subjects: Lymphoma, Non-Hodgkin*/Lymphoma, Non-Hodgkin*/Lymphoma, Non-Hodgkin*/drug therapy ; Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/drug therapy ; Immunoconjugates*/Immunoconjugates*/Immunoconjugates*/therapeutic use

• Source: Annals of hematology [Ann Hematol] 2023 Jul; Vol. 102 (7), pp. 1887-1895. Date of Electronic Publication: 2023 May 18.Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States.

• Authors : Parker C; Bristol Myers Squibb, Uxbridge, UK.; Liu FF

Subjects: Lymphoma, Large B-Cell, Diffuse*; Humans ; Cost-Benefit Analysis

• Source: Advances in therapy [Adv Ther] 2023 May; Vol. 40 (5), pp. 2355-2374. Date of Electronic Publication: 2023 Mar 22.Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet

Record details